68
Participants
Start Date
April 30, 2010
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
AUY922
70mg/m2
Docetaxel
Docetaxel 75mg/m2
Irinotecan
Iriniotecan 350mg/m2
Novartis Investigative Site, Tainan City
Novartis Investigative Site, Adelaide
Novartis Investigative Site, Bellinzona
Novartis Investigative Site, Taipei
Clinical Research Alliance Dept.ofArenaOncologyAssoc(2), Lake Success
Novartis Investigative Site, Genova
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Kuei-Shan Chiang
Novartis Investigative Site, Modena
Horizon Oncology Center, Lafayette
Novartis Investigative Site, Pisa
Novartis Investigative Site, Lyon
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas
Tyler Cancer Center Dept.ofTylerCancerCtr. (2), Tyler
Novartis Investigative Site, Napoli
Novartis Investigative Site, Ulm
USC/Kenneth Norris Comprehensive Cancer Center USC/Norris, Los Angeles
University of California at Los Angeles Dept. of UCLA (4), Los Angeles
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Singapore
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU, Baltimore
Novartis Investigative Site, Montreal
Novartis Investigative Site, Roma
Novartis Investigative Site, Utrecht
Novartis Investigative Site, Suwon
Novartis Investigative Site, Suwon
Novartis Investigative Site, Seoul
Novartis Investigative Site, Taipei
Novartis Investigative Site, Ankara
Novartis Investigative Site, Surrey
Novartis Investigative Site, Sutton
Novartis Investigative Site, Glasgow
Novartis Investigative Site, Leicester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY